Cefuroxime axetil

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Cefuroxime axetil
Cefuroxime axetil.svg
Clinical data
Trade namesZinnat, Ceftin, Ceftum
SynonymsCefuroxime 1-acetoxyethyl ester
Routes of
administration
Oral, IV, IM
Legal status
Legal status
Pharmacokinetic data
Bioavailabilitywell absorbed
MetabolismCefuroxime is not metabolized, Axetil is metabolized to acetaldehyde and acetic acid.
ExcretionUrine
Identifiers
PubChem CID
ChemSpider
UNII
ChEMBL
ECHA InfoCard100.166.374 Edit this at Wikidata
Chemical and physical data
FormulaC20H22N4O10S
Molar mass510.475 g/mol g·mol−1
3D model (JSmol)

Cefuroxime axetil, sold under the brand name Zinnat among others, is a second generation oral cephalosporin antibiotic.

It is an acetoxyethyl ester prodrug of cefuroxime which is effective orally.[1] The activity depends on in vivo hydrolysis and release of cefuroxime tablets.

It was patented in 1976 and approved for medical use in 1987.[2]

History[edit]

It was discovered by Glaxo now GlaxoSmithKline and introduced in 1987.[3] It was approved by FDA on December 28, 1987.[4] It is available by GSK as Ceftin in US[5] and Ceftum in India.[6]

See also[edit]

References[edit]

  1. ^ Walter Sneader (2005-06-23). Drug Discovery: A History. John Wiley, Chichester, UK. ISBN 0-471-89979-8.
  2. ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 494. ISBN 9783527607495.
  3. ^ "Our history - About GSK". GlaxoSmithKline. Archived from the original on 2011-05-14.
  4. ^ "Cefuroxime Axetil Monograph for Professionals". Drugs.com. Retrieved 2018-04-22.
  5. ^ "Brands". Gsksource.com. 2018-03-22. Retrieved 2018-04-22.
  6. ^ "Our products". GlaxoSmithKline.